Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AGRYLIN vs DECITABINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Agrylin (anagrelide) inhibits cyclic nucleotide phosphodiesterase III (PDE3) and reduces platelet production by interfering with megakaryocyte maturation and proliferation, likely via inhibition of cyclic AMP phosphodiesterase and modulation of intracellular calcium levels.
Decitabine is a hypomethylating agent that incorporates into DNA, inhibiting DNA methyltransferase, leading to DNA hypomethylation and reactivation of silenced genes, thereby restoring normal growth control and differentiation in hematopoietic cells.
Essential thrombocythemia (ET) to reduce elevated platelet counts and the risk of thrombotic complications
FDA-approved: Treatment of patients with myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia).,Off-label: Treatment of acute myeloid leukemia (AML), particularly in older adults not fit for intensive chemotherapy.
Adults: 0.5 mg orally once or twice daily, increased by 0.5 mg every 2 weeks to maintain platelet count <600,000/µL. Maximum dose: 10 mg/day.
Decitabine 15 mg/m² intravenously over 3 hours every 8 hours for 3 days, repeated every 6 weeks for myelodysplastic syndromes.
Terminal elimination half-life: 1.3–1.5 days (31–36 hours) in patients with ET; allows twice-daily dosing.
Terminal half-life: 0.5-1.5 hours. Short half-life; administered over 1 hour IV to maintain cytotoxic levels.
Primarily metabolized by CYP1A2 to the active metabolite 3-hydroxyanagrelide, and to a lesser extent by CYP2C19 and CYP2D6.
Decitabine is primarily metabolized via deamination by cytidine deaminase in the liver and other tissues. It is not extensively metabolized by cytochrome P450 enzymes.
Renal: 80% (primarily unchanged drug), Biliary/Fecal: 5%
Renal: 45% as unchanged drug; biliary/fecal: negligible (<5%). Hepatic metabolism accounts for remainder.
82–88% bound to plasma proteins (primarily albumin).
30-40% bound, primarily to albumin.
30–36 L (approximately 0.45–0.5 L/kg for a 70 kg adult); indicates extensive tissue distribution.
Vd: 20-40 L/kg (extensive tissue distribution, including CNS).
Oral: 65–80% (median 73%)
IV: 100%; oral: not clinically relevant (<10% due to deamination).
No specific GFR-based recommendations; use with caution in renal impairment (Cr Cl <50 m L/min) and monitor closely.
No specific dose adjustment recommended for GFR ≥30 m L/min. Insufficient data for GFR <30 m L/min. Monitor renal function and use caution.
Child-Pugh A: No adjustment. Child-Pugh B or C: Reduce initial dose by 50% and titrate cautiously.
No dose adjustment specified for Child-Pugh Class A or B. For Child-Pugh Class C, use is not recommended due to lack of data. Monitor hepatic function.
Children ≥7 years: 0.5 mg orally once or twice daily; adjust based on platelet response. Maximum: 10 mg/day. Not established for <7 years.
Safety and efficacy not established in pediatric patients. Dosing not defined.
No specific adjustment; start at lower end of dosing range (0.5 mg twice daily) and monitor renal function and platelet counts closely.
No specific dose adjustment. Monitor for increased toxicity, especially myelosuppression, in elderly patients with impaired organ function.
None
Decitabine should be administered under the supervision of a physician experienced in the use of cancer chemotherapeutic agents. Myelosuppression and worsening neutropenia may occur. Monitor complete blood counts frequently. There is no known safe level of exposure in pregnancy; women of childbearing potential should be advised to avoid pregnancy during treatment.
Cardiovascular risks: increased risk of ventricular tachycardia, QTc prolongation, and heart failure; use caution in patients with known cardiac disease.,Hematologic effects: monitor complete blood counts regularly due to risk of anemia, leukopenia, or thrombocytopenia.,Hepatic impairment: reduce dose in patients with moderate to severe hepatic impairment.,Renal impairment: use with caution in severe renal impairment.
Myelosuppression: Neutropenia, thrombocytopenia, and anemia may worsen during treatment; monitor blood counts regularly.,Hepatotoxicity: Elevations of liver enzymes and bilirubin have been reported; monitor hepatic function.,Renal toxicity: Serum creatinine elevations may occur; monitor renal function.,Fetal harm: Can cause fetal harm; advise contraception in women of reproductive potential and avoid pregnancy during treatment.,Tumor lysis syndrome: May occur; ensure adequate hydration and monitor uric acid levels.,Infusion reactions: Hypersensitivity reactions including rash, urticaria, and dyspnea have been reported.
Severe hepatic impairment,Known hypersensitivity to anagrelide or any component of the formulation
Hypersensitivity to decitabine or any component of the formulation.,Breastfeeding: Not recommended due to potential for serious adverse reactions in nursing infants.,Pregnancy: Should not be used in pregnant women or those planning pregnancy due to risk of fetal harm.
Grapefruit and grapefruit juice should be avoided as they may increase anagrelide plasma concentrations. No other specific dietary restrictions; however, maintain adequate hydration to reduce risk of crystalluria.
No known food interactions. Avoid grapefruit and grapefruit juice as a general precaution due to potential CYP3A4 interaction, though not specifically studied with decitabine. Maintain adequate hydration.
Pregnancy Category C. Anagrelide is not recommended in pregnancy. Animal studies have shown embryotoxicity and teratogenicity (e.g., increased fetal resorptions, skeletal anomalies) at doses less than the human therapeutic dose. There are no adequate and well-controlled studies in pregnant women. Use only if potential benefit justifies potential risk to fetus. First trimester: Avoid due to organogenesis risk. Second and third trimesters: Unknown risks; consider alternative therapy.
Decitabine is teratogenic in animals and has the potential to cause fetal harm in humans. In first trimester, there is a high risk of major malformations and fetal death. Second and third trimester exposure may cause growth restriction, myelosuppression, and neurodevelopmental effects. Use contraindicated in pregnancy unless benefit outweighs risk.
It is not known whether anagrelide is excreted in human milk. No M/P ratio is available. Due to potential for serious adverse reactions in breastfed infants (e.g., thrombocytopenia, cardiovascular effects), advise women not to breastfeed during treatment and for at least 7 days after last dose.
No data on presence in human milk. Due to potential for serious adverse reactions in breastfed infants (e.g., myelosuppression, carcinogenesis), breastfeeding is contraindicated during therapy and for at least 2 weeks after last dose. M/P ratio unknown.
No specific pharmacokinetic studies in pregnancy. Pregnancy-induced plasma volume expansion may lower drug concentrations, potentially requiring dose adjustment to maintain therapeutic effect. However, due to teratogenicity risks, avoid use in pregnancy. If necessary, start at lowest effective dose (0.5 mg/day) and titrate based on platelet count monitoring, not to exceed 10 mg/day.
No specific dosing adjustment guidelines exist for pregnant patients. Pregnancy may alter pharmacokinetics due to increased plasma volume and renal clearance, but no data on required dose modifications. Use lowest effective dose if unavoidable, and monitor for toxicity. Consider alternative agents.
Agrylin (anagrelide) is a phosphodiesterase III inhibitor used to reduce platelet counts in essential thrombocythemia. Monitor platelet count weekly during titration; target <600,000/µL. Avoid in patients with severe hepatic impairment (Child-Pugh C). Use with caution in cardiac disease due to risk of QT prolongation and arrhythmias. Anagrelide may increase bleeding risk, especially when combined with anticoagulants or NSAIDs. Discontinue 4-5 days before elective surgery.
Administer decitabine via IV infusion over 1 hour. Premedicate with antiemetics. Monitor CBC, LFTs, and serum creatinine prior to each cycle. Consider growth factor support for neutropenia. Avoid live vaccines during treatment. Dose adjustment required for renal impairment (Cr Cl < 30 m L/min). Not a vesicant; use central line not mandatory. Synergy with histone deacetylase inhibitors is under investigation. Hypersensitivity reactions (e.g., rash, urticaria) may occur.
Take exactly as prescribed; do not skip doses or double up.,Report any signs of bleeding (easy bruising, nosebleeds, black/tarry stools) or palpitations immediately.,Avoid NSAIDs like ibuprofen and aspirin unless directed by your doctor.,Do not consume grapefruit or grapefruit juice while taking this medication.,Inform all healthcare providers (including dentists) that you are on anagrelide.,Store at room temperature away from moisture and heat.
Take anti-nausea medication as prescribed before infusion.,Report any signs of infection such as fever, chills, or sore throat immediately.,Avoid live vaccines (e.g., MMR, flu nasal spray) while on this medication.,Use effective contraception during treatment and for at least 6 months after.,You may experience fatigue; plan rest periods and avoid driving if drowsy.,Stay well hydrated to reduce risk of kidney problems.,Rarely, you may have a severe allergic reaction; seek emergency help for hives, difficulty breathing, or swelling.
No interactions on record
"Decitabine may decrease the cardiotoxic activities of Digitoxin."
"Decitabine may decrease the cardiotoxic activities of Deslanoside."
"The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Decitabine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AGRYLIN vs DECITABINE, answered by our medical review team.
AGRYLIN is a Antineoplastic Agent that works by Agrylin (anagrelide) inhibits cyclic nucleotide phosphodiesterase III (PDE3) and reduces platelet production by interfering with megakaryocyte maturation and proliferation, likely via inhibition of cyclic AMP phosphodiesterase and modulation of intracellular calcium levels.. DECITABINE is a Antineoplastic Agent (DNA Demethylating Agent) that works by Decitabine is a hypomethylating agent that incorporates into DNA, inhibiting DNA methyltransferase, leading to DNA hypomethylation and reactivation of silenced genes, thereby restoring normal growth control and differentiation in hematopoietic cells.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AGRYLIN and DECITABINE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AGRYLIN is: Adults: 0.5 mg orally once or twice daily, increased by 0.5 mg every 2 weeks to maintain platelet count <600,000/µL. Maximum dose: 10 mg/day.. The standard adult dose of DECITABINE is: Decitabine 15 mg/m² intravenously over 3 hours every 8 hours for 3 days, repeated every 6 weeks for myelodysplastic syndromes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AGRYLIN and DECITABINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AGRYLIN is classified as Category C. Pregnancy Category C. Anagrelide is not recommended in pregnancy. Animal studies have shown embryotoxicity and teratogenicity (e.g., increased fetal resorptions, skeletal anomalies. DECITABINE is classified as Category C. Decitabine is teratogenic in animals and has the potential to cause fetal harm in humans. In first trimester, there is a high risk of major malformations and fetal death. Second an. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.